VRTX Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of 23.33% compared to Vertex Pharmaceuticals's net margin of 19.72%. Vertex Pharmaceuticals's return on equity of -6.04% beat Gilead Sciences's return on equity of 32.29%.

Vertex Pharmaceuticals has a consensus price target of $500.12, signalling upside risk potential of 10.54%. On the other hand Gilead Sciences has an analysts' consensus of $116.00 which suggests that it could grow by 6.13%. Given that Vertex Pharmaceuticals has higher upside potential than Gilead Sciences, analysts believe Vertex Pharmaceuticals is more attractive than Gilead Sciences.

Vertex Pharmaceuticals has a beta of 0.415, which suggesting that the stock is 58.544% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.86%.

Vertex Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 2.84% to investors and pays a quarterly dividend of $0.79 per share. Vertex Pharmaceuticals pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Vertex Pharmaceuticals quarterly revenues are $2.8B, which are smaller than Gilead Sciences quarterly revenues of $6.7B. Vertex Pharmaceuticals's net income of $646.3M is lower than Gilead Sciences's net income of $1.3B. Notably, Vertex Pharmaceuticals's price-to-earnings ratio is 26.10x while Gilead Sciences's PE ratio is 23.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals is 10.56x versus 4.80x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 23.33% compared to Vertex Pharmaceuticals's net margin of 21.68%. Vertex Pharmaceuticals's return on equity of -6.04% beat Eli Lilly and's return on equity of 78.25%.

Vertex Pharmaceuticals has a consensus price target of $500.12, signalling upside risk potential of 10.54%. On the other hand Eli Lilly and has an analysts' consensus of $951.98 which suggests that it could grow by 17.73%. Given that Eli Lilly and has higher upside potential than Vertex Pharmaceuticals, analysts believe Eli Lilly and is more attractive than Vertex Pharmaceuticals.

Vertex Pharmaceuticals has a beta of 0.415, which suggesting that the stock is 58.544% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.404, suggesting its less volatile than the S&P 500 by 59.63%.

Vertex Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.69% to investors and pays a quarterly dividend of $1.50 per share. Vertex Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Vertex Pharmaceuticals quarterly revenues are $2.8B, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Vertex Pharmaceuticals's net income of $646.3M is lower than Eli Lilly and's net income of $2.8B. Notably, Vertex Pharmaceuticals's price-to-earnings ratio is 26.10x while Eli Lilly and's PE ratio is 65.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals is 10.56x versus 14.90x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 23.33% compared to Vertex Pharmaceuticals's net margin of 32.71%. Vertex Pharmaceuticals's return on equity of -6.04% beat Merck &'s return on equity of 39.02%.

Vertex Pharmaceuticals has a consensus price target of $500.12, signalling upside risk potential of 10.54%. On the other hand Merck & has an analysts' consensus of $101.79 which suggests that it could grow by 26.73%. Given that Merck & has higher upside potential than Vertex Pharmaceuticals, analysts believe Merck & is more attractive than Vertex Pharmaceuticals.

Vertex Pharmaceuticals has a beta of 0.415, which suggesting that the stock is 58.544% less volatile than S&P 500. In comparison Merck & has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.863%.

Vertex Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.93% to investors and pays a quarterly dividend of $0.81 per share. Vertex Pharmaceuticals pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Vertex Pharmaceuticals quarterly revenues are $2.8B, which are smaller than Merck & quarterly revenues of $15.5B. Vertex Pharmaceuticals's net income of $646.3M is lower than Merck &'s net income of $5.1B. Notably, Vertex Pharmaceuticals's price-to-earnings ratio is 26.10x while Merck &'s PE ratio is 11.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals is 10.56x versus 3.19x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 23.33% compared to Vertex Pharmaceuticals's net margin of -907.48%. Vertex Pharmaceuticals's return on equity of -6.04% beat Moderna's return on equity of -29.23%.

Vertex Pharmaceuticals has a consensus price target of $500.12, signalling upside risk potential of 10.54%. On the other hand Moderna has an analysts' consensus of $47.64 which suggests that it could grow by 71.66%. Given that Moderna has higher upside potential than Vertex Pharmaceuticals, analysts believe Moderna is more attractive than Vertex Pharmaceuticals.

Vertex Pharmaceuticals has a beta of 0.415, which suggesting that the stock is 58.544% less volatile than S&P 500. In comparison Moderna has a beta of 1.858, suggesting its more volatile than the S&P 500 by 85.779%.

Vertex Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vertex Pharmaceuticals pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Vertex Pharmaceuticals quarterly revenues are $2.8B, which are larger than Moderna quarterly revenues of $107M. Vertex Pharmaceuticals's net income of $646.3M is higher than Moderna's net income of -$971M. Notably, Vertex Pharmaceuticals's price-to-earnings ratio is 26.10x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals is 10.56x versus 3.44x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.